Clinical characteristics of Australian treatment-naive patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real-world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first-line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced-stage disease, and 48% of patients with the early-stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients & GE;60 years of age with advanced-stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early-stage disease, and 88% in advanced-stage disease. Early progression-free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.

Automated summary

This study summarizes the clinical characteristics of 498 Australian patients with classical Hodgkin lymphoma (cHL), including baseline characteristics, histologic subtype, and treatment patterns. Patient demographics and distribution of histopathological subtypes of cHL are consistent with reported international cohorts. The most common therapy for both early and advanced-stage disease is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), and 48% of patients with early-stage disease received radiotherapy.